Business Wire

Innovation in Resistance Management: VECTRONTM T500, a New Vector Control Product, is Prequalified by the World Health Organization (WHO)

Share

VECTRONTM T500 is a new IRS product containing TENEBENALTM, the world’s first meta-diamide active ingredient (IRAC Group 30) developed by Mitsui Chemicals Agro which has a different mode of action from existing vector control products.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230313005328/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Mosquitoes in Bugesera district, Rwanda. Photographed by Mitsui Chemicals Agro.

VECTRONTM T500 will support the rotation of insecticides in line with best practice insecticide resistance management, which is critical to preserve the long-term efficacy of vector control tools. VECTRONTM T500 has outstanding efficacy against malaria vector mosquitoes including strains and populations resistant to pyrethroids and some other insecticides. It works on a variety of types of wall surfaces, including mud, and shows long residual efficacy.

VECTRONTM T500 is non-repellent, odorless and stainless formulation with low mammalian acute toxicity, and is supplied in easy-to-handle 50g aluminum sachets.

Mitsui Chemicals Agro will launch VECTRONTM T500 in sub-Saharan African countries from 2023 in line with locally required conditions of use.

OZAWA says: “Mitsui Chemicals Agro is an R&D driven chemical company, that has been developing malaria vector control products to save human lives. Our mission is to provide solutions to health challenges through the development and deployment of innovative, high-quality products. We are committed to malaria eradication and are excited about the launch of VECTRONTM T500. We appreciate the support of all our stakeholders and partners in reaching this important milestone.”

Justin McBeath CEO of IVCC added: “IVCC was established with a mission to work with partners, such as Mitsui Chemicals Agro, to accelerate the availability of new public health insecticides which will help address the significant threat of insecticide resistance in malaria vectors. We are delighted to have supported Mitsui Chemicals Agro on their achievement of the PQ-listing of this important breakthrough product which represents another significant milestone in the fight against malaria.”

Notes to Editors

Mitsui Chemicals Agro, Inc.

Mitsui Chemicals Agro is an R&D driven company that is a global provider of solutions by high-quality products and services in the agrochemicals field. The company has a history of about 100 years beginning with the manufacture and release of the first synthetic agrochemical in Japan. Mitsui Chemicals Agro has been contributing human health and comfortable life through PPM (Professional Pest Management) business, providing unique active ingredients and formulated products. Mitsui Chemicals Agro is 100% subsidiary of Mitsui Chemicals (Tokyo:4183, ISIN: JP3888300005) which has an annual sale of 1,612 billion yen in the fiscal year ending March 2022.

IVCC

IVCC is the only Product Development Partnership (PDP) working in vector control. IVCC was established in 2005, through an initial $50 million grant to the Liverpool School of Tropical Medicine (LSTM) from the Bill & Melinda Gates Foundation and has since provided ongoing support for IVCC activities. As a registered charity in the UK, IVCC is also funded by UK Aid, USAID and the Swiss Agency for Development and Cooperation to work with stakeholders to facilitate the development of novel and improved public health insecticides and formulations to combat the rapidly growing problem of insecticide resistance. In addition, IVCC is also funded by Unitaid and the Global Fund to implement catalytic market access projects, such as NgenIRS and the New Nets Project which support the rapid and scaled deployment of innovative vector control interventions. IVCC brings together partners from industry, the public sector and academia to create new solutions to prevent disease transmission. By focusing resources and targeting practical scientific solutions we accelerate the process from innovation to impact.

Reference

*1) WHO -Prequalification of Vector Control Products- VECTRONTM T500
https://extranet.who.int/pqweb/vector-control-product/vectron-t500

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Contacts for inquiries about VECTRONTM T500
International Business Div.
Mitsui Chemicals Agro, Inc.
E-mail: MCAG-Vectron@mitsuichemicals.com

Contacts for inquiries about this project
Corporate Communication Div.
Mitsui Chemicals, Inc.
URL: https://form.mitsuichemicals.com/corporate/cc_pr_csr_en

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Vertex Presents Updated Phase 1/2 Data From RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults with IgA Nephropathy and Primary Membranous Nephropathy at American Society of Nephrology Kidney Week9.11.2025 00:15:00 EET | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced updated data for povetacicept (pove) in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) from the ongoing RUBY-3 trial at the American Society of Nephrology (ASN) Kidney Week 2025 in Houston, Texas. Pove is an investigational recombinant fusion protein therapeutic and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove is the only BAFF+APRIL inhibitor in pivotal trials for multiple kidney diseases. Results were presented today as a late-breaking oral presentation (SA-OR091) and included interim data from the open-label Phase 1/2 RUBY-3 trial, where adults with IgAN and pMN received pove subcutaneously every 4 weeks. The analysis included 21 participants with IgAN and 10 participants with pMN treated with pove at the 80mg dose, of which 17 participants and 5 participants, respectively, completed the Week 48 study visit. Results in IgAN In IgAN,

Westinghouse and Hungary Establish Landmark Nuclear Fuel Partnership8.11.2025 16:00:00 EET | Press release

Westinghouse Electric Company and MVM Group signed a contract to ensure diversification of fuel supply in Hungary. This partnership brings to Paks Nuclear Power Plant (NPP) reliable supply with Westinghouse VVER fuel, manufactured in Europe. The Westinghouse VVER-440 fuel reload deliveries will start in 2028, subject to licensing activities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251107682814/en/ Westinghouse Nuclear Fuel Senior Vice President Aziz Dag, left, and Károly Mátrai, CEO of the MVM Group, signed the Paks VVER-440 contract, Nov. 7, 2025. “Our agreement with Westinghouse is a clear response to today's energy challenges and further strengthens the role of Hungary's leading base power plant in the domestic energy supply. This strategically important step will make the operation of Paks Nuclear Power Plant safer and more flexible. The diversified fuel procurement reduces external exposures and provides predicta

OMRON Releases the “Medium-Term Roadmap SF 2nd Stage”8.11.2025 08:00:00 EET | Press release

OMRON (TOKYO: 6645) has announced its “Medium-Term Roadmap Shaping the Future 2nd Stage (“SF 2nd Stage”),” covering from FY2026 to FY2030, on November 7, 2025 (JST). This Roadmap presents the Group’s vision and growth strategies through 2030, which are disclosed on our corporate website. Overview of the “Medium-Term Roadmap SF 2nd Stage” Since April 2024, OMRON has been implementing a Structural Reform Program “NEXT 2025” aimed at rebuilding our foundation for profitability and growth. With the completion of this Program in September 2025, we have shifted into a growth phase and formulated a new Roadmap looking ahead to 2030. This Roadmap identifies Business Portfolio Restructuring as a core strategy. We have defined Thirteen Focus Businesses to drive the Group’s future growth. By accelerating our selection and concentration efforts, we aim to build a “distinctive” business portfolio that maximizes overall Group growth. Furthermore, to maximize the growth potential of our Focus Busines

26 th UN Tourism General Assembly kicks off in Riyadh7.11.2025 23:13:00 EET | Press release

The 26th session of the UN Tourism General Assembly opened today in Riyadh, marking a historic first for the Gulf Cooperation Council (GCC) region and the largest Assembly since UN Tourism was founded 50 years ago. Around 160 delegations from member states including ministers, senior officials, and leaders from across industry and civil society are coming together to celebrate five decades of international collaboration under the theme “AI-Powered Tourism: Redefining the Future.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251107012471/en/ 26th UN Tourism General Assembly kicks off in Riyadh The Assembly is hosted by Saudi Arabia’s Ministry of Tourism, with extensive cooperation and planning alongside UN Tourism and a wide range of partners. This collaboration underscores the Kingdom’s dedication to advancing the industry and facilitating impactful dialogue on the global stage. For half a century, UN Tourism has advanced

Xsolla Partners With Deloitte Turkiye and Lorien Accelerator as Category Sponsor for Gaming Awards at Fast 50 Türkiye 2025 Program7.11.2025 20:11:00 EET | Press release

Xsolla, a leading global video game commerce company that helps developers launch, grow, and monetize their games, is proud to announce its sponsorship of the Gaming Awards segment at the Deloitte Technology Fast 50 Türkiye 2025 Program, organized in collaboration with Lorien Accelerator. The event will take place on December 10, 2025, and will recognize Turkey’s top high-growth companies across various industries, with a special focus on the dynamic gaming sector. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251107671030/en/ Graphic: Xsolla As the Gaming Awards category sponsor, Xsolla will receive significant brand exposure through prominent logo placements across all event materials, including digital platforms, official event signage, and other promotional materials. In addition to this visibility, Xsolla’s participation includes an exclusive opportunity to engage in a panel discussion focused on Turkey’s rapidly growi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye